Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of ibrutinib (PCI-32765) in
relapsed/refractory de novo activated B-cell (ABC) and germinal-cell B-Cell (GCB) Diffuse
Large B-cell Lymphoma (DLBCL).